JPWO2021100728A1 - - Google Patents
Info
- Publication number
- JPWO2021100728A1 JPWO2021100728A1 JP2021558405A JP2021558405A JPWO2021100728A1 JP WO2021100728 A1 JPWO2021100728 A1 JP WO2021100728A1 JP 2021558405 A JP2021558405 A JP 2021558405A JP 2021558405 A JP2021558405 A JP 2021558405A JP WO2021100728 A1 JPWO2021100728 A1 JP WO2021100728A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dispersion Chemistry (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019209630 | 2019-11-20 | ||
| JP2019209630 | 2019-11-20 | ||
| PCT/JP2020/042889 WO2021100728A1 (ja) | 2019-11-20 | 2020-11-18 | ６，７－不飽和－７－カルバモイルモルヒナン誘導体含有固形製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2021100728A1 true JPWO2021100728A1 (https=) | 2021-05-27 |
| JP7582961B2 JP7582961B2 (ja) | 2024-11-13 |
Family
ID=75980561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021558405A Active JP7582961B2 (ja) | 2019-11-20 | 2020-11-18 | ６，７－不飽和－７－カルバモイルモルヒナン誘導体含有固形製剤 |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP4062973A4 (https=) |
| JP (1) | JP7582961B2 (https=) |
| WO (1) | WO2021100728A1 (https=) |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999002158A1 (fr) * | 1997-07-11 | 1999-01-21 | Toray Industries, Inc. | Compositions medicinales stables, contenant des derives de 4,5-epoxymorphinane |
| WO2003077867A2 (en) * | 2002-03-14 | 2003-09-25 | Euro-Celtique, S.A. | Naltrexone hydrochloride compositions |
| CN101406474A (zh) * | 2008-02-28 | 2009-04-15 | 云南绿野生物医药有限公司 | 纳美芬注射液及其制备方法 |
| CN101732243A (zh) * | 2008-11-26 | 2010-06-16 | 重庆医药工业研究院有限责任公司 | 一种稳定的甲基纳曲酮注射液及其制备方法 |
| WO2013172297A1 (ja) * | 2012-05-14 | 2013-11-21 | 塩野義製薬株式会社 | ６，７－不飽和－７－カルバモイルモルヒナン誘導体含有製剤 |
| CN103877016A (zh) * | 2014-04-11 | 2014-06-25 | 成都苑东药业有限公司 | 一种盐酸纳洛酮注射液药物组合物及其制备方法 |
| US20160067339A1 (en) * | 2012-06-05 | 2016-03-10 | Neuroderm, Ltd. | Compositions comprising apomorphine and organic acids and uses thereof |
| JP2018500350A (ja) * | 2014-12-23 | 2018-01-11 | ニューロダーム リミテッドＮｅｕｒｏｄｅｒｍ Ｌｔｄ | アポモルヒネの結晶形態およびその使用 |
| JP2018065775A (ja) * | 2016-10-21 | 2018-04-26 | 東洋カプセル株式会社 | ナルフラフィン塩酸塩を含有するカプセル充填用組成物、軟カプセル剤及びその製造方法 |
| WO2018124062A1 (ja) * | 2016-12-26 | 2018-07-05 | 塩野義製薬株式会社 | 含量均一性を改善した製剤の製造方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19813661A1 (de) | 1997-08-01 | 1999-02-04 | Solvay Pharm Gmbh | Gegen Racemisierung stabilisierte pharmazeutische Zubereitungen von Cilansetron |
| WO2006126529A1 (ja) | 2005-05-25 | 2006-11-30 | Shionogi & Co., Ltd. | ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体 |
| CA2784407A1 (en) | 2009-12-17 | 2011-07-14 | Cima Labs Inc. | Abuse-resistant formulations |
| RU2607084C2 (ru) | 2010-11-12 | 2017-01-10 | Сионоги Энд Ко., Лтд. | Кристаллы производных 6,7-ненасыщенного-7-карбамоилморфинана и способ их получения |
| JP6030357B2 (ja) | 2012-07-03 | 2016-11-24 | サンスター株式会社 | オレウロペイン含有組成物 |
| WO2018021518A1 (ja) * | 2016-07-29 | 2018-02-01 | 東レ株式会社 | 光安定性の向上した固形製剤 |
-
2020
- 2020-11-18 JP JP2021558405A patent/JP7582961B2/ja active Active
- 2020-11-18 WO PCT/JP2020/042889 patent/WO2021100728A1/ja not_active Ceased
- 2020-11-18 EP EP20890315.3A patent/EP4062973A4/en active Pending
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999002158A1 (fr) * | 1997-07-11 | 1999-01-21 | Toray Industries, Inc. | Compositions medicinales stables, contenant des derives de 4,5-epoxymorphinane |
| WO2003077867A2 (en) * | 2002-03-14 | 2003-09-25 | Euro-Celtique, S.A. | Naltrexone hydrochloride compositions |
| CN1652752A (zh) * | 2002-03-14 | 2005-08-10 | 欧罗赛铁克股份有限公司 | 盐酸纳曲酮组合物 |
| CN101406474A (zh) * | 2008-02-28 | 2009-04-15 | 云南绿野生物医药有限公司 | 纳美芬注射液及其制备方法 |
| CN101732243A (zh) * | 2008-11-26 | 2010-06-16 | 重庆医药工业研究院有限责任公司 | 一种稳定的甲基纳曲酮注射液及其制备方法 |
| WO2013172297A1 (ja) * | 2012-05-14 | 2013-11-21 | 塩野義製薬株式会社 | ６，７－不飽和－７－カルバモイルモルヒナン誘導体含有製剤 |
| US20160067339A1 (en) * | 2012-06-05 | 2016-03-10 | Neuroderm, Ltd. | Compositions comprising apomorphine and organic acids and uses thereof |
| CN103877016A (zh) * | 2014-04-11 | 2014-06-25 | 成都苑东药业有限公司 | 一种盐酸纳洛酮注射液药物组合物及其制备方法 |
| JP2018500350A (ja) * | 2014-12-23 | 2018-01-11 | ニューロダーム リミテッドＮｅｕｒｏｄｅｒｍ Ｌｔｄ | アポモルヒネの結晶形態およびその使用 |
| JP2018065775A (ja) * | 2016-10-21 | 2018-04-26 | 東洋カプセル株式会社 | ナルフラフィン塩酸塩を含有するカプセル充填用組成物、軟カプセル剤及びその製造方法 |
| WO2018124062A1 (ja) * | 2016-12-26 | 2018-07-05 | 塩野義製薬株式会社 | 含量均一性を改善した製剤の製造方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7582961B2 (ja) | 2024-11-13 |
| EP4062973A1 (en) | 2022-09-28 |
| WO2021100728A1 (ja) | 2021-05-27 |
| EP4062973A4 (en) | 2023-11-29 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230907 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20231019 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20240122 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240723 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240919 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20241022 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20241031 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7582961 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |